Marshall Wace, LLP Dia Medica Therapeutics Inc. Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
A detailed history of Marshall Wace, LLP transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 61,719 shares of DMAC stock, worth $422,775. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,719
Previous 18,829
227.79%
Holding current value
$422,775
Previous $71,000
238.03%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DMAC
# of Institutions
59Shares Held
6.07MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.54MShares$10.5 Million0.0% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX650KShares$4.45 Million4.32% of portfolio
-
Geode Capital Management, LLC Boston, MA630KShares$4.32 Million0.0% of portfolio
-
First Manhattan CO New York, NY606KShares$4.15 Million0.01% of portfolio
-
Bleichroeder LP New York, NY382KShares$2.62 Million0.47% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $181M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...